CleveXel Pharma to license two new oncology patents from SATT Sud Est
6 October 2014 | By CleveXel Pharma
They will address the treatment of bone marrow cancers and the diagnosis of patients who are resistant to standard treatments...
List view / Grid view
News
OBN celebrates the stars of UK Life Sciences
3 October 2014 | By OBN
OBN revealed last night the winners of its Annual Awards celebrating the best of UK life sciences – the innovators, fundraisers and dealmakers who underline the pre-eminence of the UK sector in the global marketplace...
Allied-Bristol Life Sciences appoints Satish Jindal to lead the discovery of drug candidates from leading academic institutions
3 October 2014 | By Allied-Bristol Life Sciences
Allied-Bristol Life Sciences today announced that Satish Jindal, Ph.D., formerly Vice President of R&D within Bristol-Myers, has been appointed to lead the company’s efforts to identify and foster development of biopharmaceutical innovations from top U.S. university research institutions...
Agar Scientific appoints Paul Balaş as new Technical Sales Manager
3 October 2014 | By Agar Scientific
Paul joins Agar Scientific from Ronexprim SRL – where he was an Executive Director and the Area Sales Manager for PANalytical X-ray equipment and FEI electronic microscopes in Romanian territories...
Lilly to discontinue development of Tabalumab based on efficacy results in phase 3 lupus studies
2 October 2014 | By Eli Lilly and Company
Eli Lilly and Company announced today it will discontinue development of tabalumab -- being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) -- due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns. ..
rfC included in the new draft 5.1.10 by the European Pharmacopeia
News from the European Pharmacopoeia:
Bristol-Myers Squibb to announce results for Third Quarter on October 24
2 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company will announce results for the third quarter on Friday, October 24, 2014...
Thermo Scientific TGA-IR Module enhances materials characterization for users of FT-IR Spectrometers
Scientists involved in materials characterization, process validation and product failure analysis can gather more valuable data by combining two powerful analytical techniques. The new Thermo Scientific TGA-IR Module provides users of Thermo Scientific FT-IR spectrometers with enhanced performance when combining Thermal Gravimetric Analysis (TGA) and FT-IR spectroscopy.
Daiichi Sankyo and Daiichi Sankyo Espha submit supplemental New Drug Application in Japan for “Cravit® Tablets, Granules” and “Levofloxacin Tablets, Granules DSEP”
1 October 2014 | By Daiichi Sankyo
Daiichi Sankyo Company Limited announced that it and its domestic generic subsidiary, Daiichi Sankyo Espha Co., Ltd. have submitted a supplemental New Drug Application (sNDA) in Japan...
Asthma: Spiriva® (tiotropium) Respimat® becomes the only LAMA licensed in asthma care
1 October 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that adult asthma patients could benefit from a new treatment...
Cardio3 BioSciences announces new business development strategy to broaden its product pipeline
1 October 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces that it has recently increased its business development activities, building on its core expertise in cellular therapies and in cardiovascular diseases...
DKSH extends partnership with Novo Nordisk in Malaysia
1 October 2014 | By DKSH Business Unit Healthcare
DKSH, the leading Market Expansion Services provider with a focus on Asia, signed an agreement to provide commercial and distribution services to Novo Nordisk, a global healthcare company with 90 years of experience in diabetes care, in Malaysia...
Celerion expands ophthalmological capabilities to patient populations in collaboration with Queen’s University, Belfast
30 September 2014 | By Celerion
Celerion, announces the expansion of ophthalmological services in our Belfast, Northern Ireland UK facility, by building on our successful relationship with Queen’s University in Belfast...
Quotient Clinical showcases RapidFACT™ and six poster publications at AAPS
30 September 2014 | By kdm communications
Quotient Clinical, the Translational Pharmaceutics™ company, will present the third annual RapidFACT™ (Rapid Formulation development And Clinical Testing) User Group Meeting...
US allergic rhinitis treatment market value to see fourfold increase by 2018, says GlobalData
30 September 2014 | By GlobalData
The US market value for allergic rhinitis treatment will rise rapidly from $172.5 million in 2013 to $688.25 million by 2018, at an impressive Compound Annual Growth Rate (CAGR) of 31.88%, according to research and consulting firm GlobalData...
